Novo Nordisk (Brazil) Today
| N1VO34 Stock | BRL 76.20 0.31 0.41% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Novo Nordisk is trading at 76.20 as of the 26th of November 2024, a 0.41 percent down since the beginning of the trading day. The stock's open price was 76.51. Novo Nordisk has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Novo Nordisk AS are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Moving together with Novo Stock
Moving against Novo Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Novo Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novo Nordisk's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novo Nordisk or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Pres | Lars Jorgensen |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Novo Nordisk AS (N1VO34) is traded on Sao Paulo Exchange in Brazil and employs 54,393 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 1.67 T. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novo Nordisk's market, we take the total number of its shares issued and multiply it by Novo Nordisk's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novo Nordisk AS operates under Healthcare sector and is part of Biotechnology industry. The entity has 2.25 B outstanding shares.
Novo Nordisk generates positive cash flow from operations, but has no cash available
Check Novo Nordisk Probability Of Bankruptcy
Novo Nordisk AS Risk Profiles
Although Novo Nordisk's alpha and beta are two of the key measurements used to evaluate Novo Nordisk's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.71 | |||
| Standard Deviation | 2.17 | |||
| Variance | 4.73 | |||
| Risk Adjusted Performance | (0.09) |
Novo Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novo Nordisk without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
Novo Nordisk Corporate Management
Elected by the shareholders, the Novo Nordisk's board of directors comprises two types of representatives: Novo Nordisk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novo. The board's role is to monitor Novo Nordisk's management team and ensure that shareholders' interests are well served. Novo Nordisk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novo Nordisk's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marcus Schindler | Head EVP | Profile | |
| Monique Carter | Head VP | Profile | |
| Maziar Doustdar | Head VP | Profile | |
| Henrik Wulff | Head VP | Profile | |
| Ludovic Helfgott | Head VP | Profile |
Additional Information and Resources on Investing in Novo Stock
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..